Chengdu High-Tech Zone Launches Digital-Intelligent Healthcare Innovation Consortium and Alliance to Boost Industry Growth

To seize the major strategic opportunities presented by the development of artificial intelligence (AI), accelerate the high-quality development of the digital-intelligent healthcare industry, and empower Chengdu High-Tech Zone in its capacity as a National Pilot Zone for the Innovative Development of New-Generation AI and a National Leading Zone for AI Innovation and Application, the “Park Establishment and Full Occupancy” Eco-Salon for the Digital-Intelligent Healthcare Industry, together with the Inaugural Conference of the Digital-Intelligent Healthcare Innovation Consortium, was held at the Chengdu Frontier Medical Center on January 20.

It is understood that this event centers on promoting exchange and cooperation in the digital intelligence healthcare industry, establishing a new platform for industrial collaboration, stimulating innovation vitality across related sectors, and working together to drive the high-quality development of the digital economy and health industry in Chengdu and western China.

Conference Venue

At the event, the “Digital Intelligence Healthcare Innovation Consortium” was officially announced. According to the introduction, the consortium (hereinafter referred to as the “Consortium”) is jointly established by innovation and technology transfer institutions such as the Sichuan Provincial Medical Science and Technology Education Center and the Western China Medical Technology Transfer Center, leading medical institutions including West China Hospital and Sichuan Provincial People’s Hospital, as well as globally leading multinational pharmaceutical and medical device companies such as Takeda China and Medtronic. The Consortium aims to accelerate the high-quality development of the digital intelligence healthcare industry. In the future, it will stimulate industry innovation, set industry benchmarks, and promote the coordinated development of the innovation and industrial chains in digital intelligence healthcare through a series of initiatives, including establishing a government-enterprise dialogue platform and creating an innovation competition platform for digital intelligence healthcare.

Inauguration Ceremony of the Digital Intelligence Healthcare Innovation Consortium

Meanwhile, the “Chengdu High-Tech Zone Digital Intelligence Medical Innovation Alliance” (hereinafter referred to as the “Alliance”) was officially established during the event. The Sichuan Western Pharmaceutical Technology Transfer Center serves as the chairing entity, with more than 60 member units, including Huajing Digital Healthcare, Brain Dynamics Aurora, Shangyi Information Technology, Baichuan Intelligence, and Yuanyi Capital. As the executive body of the consortium, the Alliance is primarily responsible for leading the implementation of the consortium’s work plan, organizing and carrying out specific business activities, and promoting achievement transformation, technological innovation, and industrial collaboration.

Lei Juan

Inauguration Ceremony of the Chengdu High-Tech Zone Digital Intelligence Healthcare Innovation Alliance

“The establishment of the consortium and alliance has transformed us from operating in a fragmented manner into a cohesive ‘community of partners,’ creating highly promising prospects,” said Bi Mingshuai, Director of the Sichuan Provincial Medical Science, Technology and Education Center. He expressed confidence that this initiative will provide robust support for technological innovation and the translation of scientific achievements in the digital intelligence healthcare industry, while offering application scenarios and demonstration platforms for the promotion of technological outcomes.

“The establishment of this consortium and alliance represents another significant initiative by the Chengdu High-Tech Zone to seize opportunities in the emerging ‘AI+’ sector. We aim to attract upstream and downstream enterprises in the digital intelligence healthcare industry to the zone, thereby comprehensively strengthening and fortifying the industrial chain. Furthermore, we seek to continuously enhance the capacity for originating industrial innovations, injecting fresh vitality into regional industrial development,” stated a representative from the Chengdu High-Tech Zone Administration.

Group Photo of the Chengdu High-Tech Zone Digital Intelligence Medical Innovation Alliance

To further promote the interconnectivity of cutting-edge technology and innovation in the industry, more than 20 domestic and international experts gathered at the event to jointly discuss future trends, technological innovations, and industry practices in the digital intelligence healthcare sector.

Among them, guests including Bi Mingshuai, Director of the Sichuan Provincial Medical Science and Technology Education Center; Huang Sheng, Head of the Information Management Department at West China Second University Hospital’s Gaoxin Maternal and Child Health Hospital, Sichuan University; and Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical Company and President of Takeda China, delivered reports on themes such as “Effective Mechanisms for Collaborative Innovation and Translation between Scientific Research and the Digital Intelligence Industry,” “Digital Intelligence Empowering Clinical Practice,” and “Expanding Dimensions in China, Creating the Future with Digital Innovation.” They provided in-depth interpretations of current industry development trends and the opportunities and challenges faced, offering new perspectives for the development of digital intelligence healthcare enterprises.

Bi Mingshuai

Huang Sheng

Shan Guohong

Shan Guohong stated that on the morning of January 20, Takeda Pharmaceutical signed a cooperation agreement with the Chengdu High-Tech Zone to invest in establishing an innovation center for Takeda’s digital health initiatives in China. Going forward, Takeda China Innovation Center will collaborate with industry chain partners to strive for comprehensive accessibility of rare disease treatments through digital innovation. Meanwhile, it will actively participate in collaborative ecosystems, leveraging digital technologies to enhance the quality and efficiency of medical services, thereby contributing to industrial development in the Chengdu High-Tech Zone, Chengdu City, and even the broader western region of China.

During the roundtable discussion session, guests including Zhou Yongzhao, Director of the Whole-Process Management Center at West China Hospital of Sichuan University; Cai Lulu, Deputy Director of the Department of Science and Technology at Sichuan Provincial People’s Hospital and Professor at the University of Electronic Science and Technology of China; Gu Qing, Vice President of Takeda China and Head of the Digital Technology Team; and Zhang Hui, Head of Central Government Affairs and Policy for Medtronic Greater China, engaged in a dialogue on the topic of “Clinical Translation, Application, and Collaboration Models in Digital and Intelligent Healthcare.” Meanwhile, guests such as Sun Yanxin, Vice President of Baichuan Intelligence; Zhen Peng, Deputy General Manager of BioMap; Lei Chi, Co-founder and General Manager of Chengdu Shangyi Information Technology; Lai Zhiyuan, Vice President of BrainDong Aurora Medical Technology Co., Ltd.; and Song Yiran, Managing Director at Yuan Yi Capital, exchanged views on the topic of “Innovation in Digital and Intelligent Technology-Driven Medical Devices: Synergistic Advancement in R&D, Commercialization, and Government Support.”

Roundtable Discussion I

Roundtable Discussion II

“As a local enterprise in Chengdu High-Tech Zone, we have gained many new concepts through exchanges and discussions with experts. In the future, our company will continue to strengthen communication and cooperation with members of the consortium to jointly promote the healthy development of the digital intelligence medical industry in Chengdu High-Tech Zone,” said a corporate representative from Chengdu Shangyi Future Medical Technology Co., Ltd.

As the primary engine of Chengdu’s economic development, Chengdu High-Tech Zone is actively building the National New Generation Artificial Intelligence Innovation Development Pilot Zone and the National Artificial Intelligence Innovation Application Leading Zone, providing a solid foundation for the cross-sector integration of artificial intelligence with the pharmaceutical and health industries.

As of now, Chengdu High-Tech Zone has gathered more than 140 companies in the digital intelligence medical industry, covering hot sectors such as drug R&D, medical devices, health management, and medical services, with a number of star enterprises emerging locally in Chengdu.

Moving forward, Chengdu High-Tech Zone will continue to leverage platform development, government-enterprise exchanges, and deepened collaboration to thoroughly explore innovation in the digital-intelligent healthcare industry and ecosystem building. This will accelerate the formation of a competitive high-end industrial cluster and further promote high-level integrated cluster development within the sector.